Eicosapentaenoic Acid Improves Hepatic Metabolism and Reduces Inflammation Independent of Obesity in High-Fat-Fed Mice and in HepG2 Cells
Albracht-Schulte K, Gonzalez S, Jackson A, Wilson S, Ramalingam L, Kalupahana NS, Moustaid-Moussa N
Nutrients · 44 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio en animales (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas, más trabajo en animales o laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- U.S. Department of Agriculture
- Organización sin fines de lucro
- American Heart Association
- Universidad u hospital
- Texas Tech University
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute of Food and Agriculture
- Gobierno
- National Center for Complementary and Integrative Health
- Gobierno
- NCCIH NIH HHS
- Gobierno
- NIH HHS
- Subvenciones
- U.S. Department of Agriculture (2017-67011-26029); National Institutes of Health (1r15at008879-01a1); National Center for Complementary and Integrative Health (R15 AT008879)
Según 8 financiadores declarados.
Publicación
- Publicado
- 2019-03-12 · Nutrients · vol. 11 · número 3 · pág. 599
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 60 citas · más que el 96% de estudios similares · 4.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 70 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Peroxisome Proliferator-Activated Receptors · Diet, Metabolism, and Disease
- Palabras clave
- Eicosapentaenoic acid, Steatosis, Endocrinology, Internal medicine, Fatty acid synthase, Biology, Lipid metabolism, Polyunsaturated fatty acid, Nonalcoholic fatty liver disease, Fatty liver, CD36, Inflammation, Fatty acid metabolism, Fatty acid, Metabolism, Medicine, Biochemistry, Receptor
- MeSH
- liver, animals, mice, inbred c57bl, humans, mice, obesity, eicosapentaenoic acid, fatty acids, micrornas, gene expression regulation, lipid peroxidation, male, lipid metabolism, hep g2 cells, diet, high-fat
7 autores
- Kembra Albracht‐Schulte🇺🇸Texas Tech University
- Samantha Gonzalez🇺🇸Texas Tech University
- Abigail Jackson🇺🇸Texas Tech University
- Savanna Wilson🇺🇸Texas Tech University
- Latha Ramalingam🇺🇸Texas Tech University
- Nishan S. Kalupahana🇱🇰🇺🇸University of Peradeniya; Texas Tech University
- Naïma Moustaïd‐Moussa🇺🇸 · autor de correspondenciaTexas Tech University
Resumen
El texto original del estudio, en el idioma en que se publicó.
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide, concurrent with increased obesity. Thus, there is urgent need for research that can lead to effective NAFLD prevention/treatment strategies. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), including eicosapentaenoic acid (EPA), improve inflammation- and dyslipidemia-related metabolic disorders; however, mechanisms mediating the benefits of n-3 PUFAs in NAFLD treatment are less understood. We previously reported that EPA reversed obesity-induced hepatic steatosis in high-fat (HF)-fed B6 mice. Utilizing a combination of biochemical analyses of liver tissues from HF and HF-EPA-fed mice and a series of in vitro studies in tumor necrosis factor-alpha (TNF-α)-stimulated HepG2 cells, we dissect the mechanistic effects of EPA in reducing hepatic steatosis, including the role of EPA-targeted microRNAs (miRNA). With EPA, hepatic lipid metabolism was improved in HF-EPA mice, as indicated by decreased protein and messenger RNA (mRNA) levels of fatty acid synthase (FASN) and acetyl-CoA carboxylase (Acaca) gene, and increased mRNA levels for the peroxisome proliferator activated receptor-α (Pparα), and carnitine palmitoyltransferase (Cpt) 1a and 2 genes in the HF-EPA mice. Additionally, inflammation was reduced, as shown by decreased tumor necrosis factor-alpha (Tnfα) gene expression. Accordingly, EPA also significantly reduced FASN and ACACA mRNAs in human HepG2 cells. Glycolysis, estimated by extracellular acidification rate, was significantly reduced in HepG2 cells treated with EPA vs. vehicle. Furthermore, we identified several miRNAs that are regulated by EPA in mouse liver, including miR-19b-3p, miR-21a-5p, and others, which target lipid metabolism and inflammatory pathways. In conclusion, our findings provide novel mechanistic evidence for beneficial effects of EPA in NAFLD, through the identification of specific genes and miRNAs, which may be further exploited as future NAFLD therapies.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.